From Biology to Best Practice: Sequencing Current and Emerging Therapies in EGFR-Mutated NSCLC Beyond Progression

Please visit answersincme.com/860/102251349-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Charles L. Daley, MD, ATSF, FCCP; and David E. Griffith, MD, ATSF, FCCP. In this activity, experts in MAC lung disease discuss emerging first-line treatments and guideline-concordant, patient-centered strategies to individualize care for patients with newly diagnosed or refractory disease. Upon completion of this activity, participants should be better able to: Review the clinical profiles of emerging first-line treatments for Mycobacterium avium complex (MAC) lung disease in the context of standard of care regimens; Apply guideline-concordant strategies to develop individualized treatment plans for patients with newly diagnosed and refractory MAC lung disease; and Outline patient-centered strategies to enhance outcomes for patients with MAC lung disease receiving pharmacologic treatment.

Please visit answersincme.com/860/CME-26-207477-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vallerie V. McLaughlin, MD; and Richard Channick, MD. In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH. Upon completion of this activity, participants should be better able to: Describe the rationale for risk-based treatment intensification strategies in patients with PAH. Identify clinical indicators warranting escalation of therapy in patients with intermediate- or high-risk PAH. Outline an evidence-based, personalized approach to integrating novel add-on therapies into treatment plans for patients with PAH. undefined In this activity, experts in pulmonary arterial hypertension (PAH) discuss strategies for personalized risk-based intensification of therapy for patients with PAH.

Please visit answersincme.com/860/014832-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Anne E. O'Donnell, MD; andPatrick Flume, MD. In this activity, experts in bronchiectasis discuss best practices for identifying, diagnosing, and treating CF and non-CF bronchiectasis. Upon completion of this activity, participants should be better able to:Distinguish between underlying causes of bronchiectasis that provide the rationale for targeting neutrophil inflammation. Outline recommended multidisciplinary strategies to promptly recognize and diagnose bronchiectasis. Describe the design and eligibility criteria of ongoing trials evaluating neutrophil-targeted therapies for bronchiectasis. This session is supported by Boehringer Ingelheim Pharmaceuticals, Inc. Exhibitors and supporters of NACFC include manufacturers of CF drugs, medical device companies, pharmacies, hospitals, and other related organizations. The Cystic Fibrosis Foundation does not support nor endorse the products or services of NACFC 2026 exhibitors and supporters.

Please visit answersincme.com/QRE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Theresa W. Guilbert, MD, MS. In this activity, an expert in childhood asthma discusses the use of biologics for moderate to severe pediatric asthma. Upon completion of this activity, participants should be better able to: Identify the impact of type 2 inflammation on lung function in pediatric patients with asthma; Recognize best practices for incorporating biologics into the treatment of type 2 inflammatory pediatric asthma; and Review the clinical profiles of biologic therapies for type 2 inflammatory asthma in pediatric patients. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/860/cvdprostate-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Cookson, MD; Alicia Morgans, MD, MPH; and Avirup Guha, MD, MBBS, MPH, FAHA, FACC, FESC, FICOS. In this activity, experts in prostate cancer discuss cardiovascular risk in patients receiving androgen-deprivation therapy (ADT). Upon completion of this activity, participants should be better able to: Evaluate the impacts of prostate cancer and ADT on cardiovascular risk; Translate the latest research for cardiovascular management of patients on ADT to clinical practice; and Design personalized treatment approaches to optimize ADT across treatment settings.